SPX3,831.39+6.06 0.16%
DIA309.71-1.14 -0.37%
IXIC11,322.24+194.39 1.75%

Immunome Announces Initiation Of Phase 1b Study of IMM-BCP-01 For The Treatment Of COVID-19

First study subject has been dosed in a single dose/dose escalation study of recently diagnosed COVID-19 patients Study will evaluate safety as the primary end point with pharmacokinetics (PK) and virology as

Benzinga · 06/09/2022 08:01
  • First study subject has been dosed in a single dose/dose escalation study of recently diagnosed COVID-19 patients
  • Study will evaluate safety as the primary end point with pharmacokinetics (PK) and virology as secondary assessments